Drugs / recombinant adenovirus-hIFN-beta
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00066404 | Apr 2003 → Jan 2006 | cancer | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant adenovirus-hIFN-beta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00066404 ↗ |
| Known as | Ad.IFN-beta | “We previously showed that a single intrapleural dose of an adenoviral vector expressing interferon-beta (Ad.IFN-beta) in patients with malignant pleural mesothelioma (MPM) or...” PMID 20068553 ↗ Jan 2010 |
| Route | Other | “Patients receive BG00001 via an intrapleural catheter on day 1.” NCT00066404 ↗ |